NCT06559072View on ClinicalTrials.gov

Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

522

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

September 1, 2026

Conditions
Subarachnoid HemorrhageSubarachnoid Hemorrhage, AneurysmalAneurysmal Subarachnoid HemorrhageHemorrhage, Aneurysmal Subarachnoid
Interventions
DRUG

Atorvastatin

On the basis of routine treatment for aneurysmal subarachnoid hemorrhage, atorvastatin was administered at an ultra early stage at a dose of 40mg/d for 14 consecutive days

Trial Locations (1)

Unknown

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
collaborator

Tianjin Medical University General Hospital

OTHER

lead

The George Institute

OTHER